HCC1500 Xenograft Model Service for Breast Cancer

The HCC1500 xenograft model serves as a translationally relevant in vivo platform for evaluating the efficacy of novel endocrine therapies and targeted agents against Estrogen Receptor-positive (ER+), Luminal breast cancer. Alfa Cytology offers comprehensive HCC1500 xenograft model services, leveraging our deep expertise in oncology and model construction to provide robust, high-fidelity data that accelerates your preclinical drug discovery pipeline.

Overview of HCC1500 Xenograft Model for Breast Cancer

The HCC1500 cell line is a pivotal human mammary carcinoma model originally derived from the primary tumor of a 32-year-old metastatic breast cancer patient. It is classically defined by its robust expression of the Estrogen Receptor (ER) and typically demonstrates variable expression of the Progesterone Receptor (PR), while being negative for HER2 (ERBB2) amplification. This profile categorizes HCC1500 as a faithful representation of Luminal breast cancer, specifically the difficult-to-treat subsets often associated with early-onset disease or pre-menopausal patients.

In vivo, the HCC1500 xenograft model reliably recapitulates the histological and hormonal hallmarks of clinical ER+ breast cancer. Its consistent dependency on estrogen signaling makes it an exceptional tool for studying endocrine pathway signaling, hormone-receptor-co-activator interactions, and secondary resistance mechanisms following standard treatments like aromatase inhibitors or SERDs (Selective Estrogen Receptor Degraders).

Cell Line Information: HCC1500

The HCC1500 cell line displays a stable epithelial-like morphology in vitro and maintains its core hormonal and phenotypic markers seamlessly upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the HCC1500 model throughout the lifecycle of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the HCC1500 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, estrogen supplementation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for ER/PR status and PK/PD profiling. Leveraging our expertise in ER-positive luminal breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of HCC1500 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the HCC1500 xenograft model:

• Cell Culture & Quality Control: HCC1500 cells are cultivated in specialized growth media supplemented according to optimized protocols. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation & Hormone Supplementation: Standardized immunocompromised mice are selected based on the study design and allowed to acclimate to our facility. Given the ER+ nature of the model, mice are supplemented with exogenous estrogen (e.g., via slow-release pellets) to ensure optimal in vivo engraftment and tumor growth.
• Precision Inoculation: A highly viable, calibrated suspension of HCC1500 cells is prepared and blended with a biological matrix carrier to enhance cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. HCC1500 Xenograft Model Construction Workflow

Case Study - HCC1500 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the HCC1500 xenograft model was utilized to evaluate the efficacy of a novel cell-cycle checkpoint inhibitor targeting ER+ tumors. Our technical team achieved highly reproducible tumor engraftment and uniform growth curves across all experimental arms under optimized hormone-supplemented conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group.

Why Choose Alfa Cytology?

Choosing the right partner for your ER-positive breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Hormone-Dependent Model Profiling: Deep expertise in establishing and validating aggressive receptor-positive human cell lines with specialized supplementation protocols.
• Technical Reproducibility: Refined inoculation procedures that lead to uniform tumor growth kinetics and minimize intra-group variability.
• Comprehensive Readouts: Full capacity for downstream analysis, including multiparametric flow cytometry, IHC for hormonal markers (ER, PR, Ki67), and PK/PD tissue processing.
• Rigorous Integrity: Scientific approaches aligned with international standards for translational oncology research.

Contact Us

Are you looking to advance your therapeutic pipeline against luminal, hormone-receptor-positive breast cancer using the robust HCC1500 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please reach out to us today to speak directly with an oncology specialist, or contact us to request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.